Summit Therapeutics And Lunit Announce Agreement To Apply Ai-Powered Scope Io Platform For Tumor Microenvironment Analysis In Immuno-Oncology Development
Oct 23 (Reuters) - Lunit Inc. 328130.KQ:
SUMMIT THERAPEUTICS AND LUNIT ANNOUNCE AGREEMENT TO APPLY AI-POWERED SCOPE IO PLATFORM FOR TUMOR MICROENVIRONMENT ANALYSIS IN IMMUNO-ONCOLOGY DEVELOPMENT
Further company coverage: 328130.KQ